{
  "paper_metadata": {
    "pmid": "37371673",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for BRCA2, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.9502-1G>A",
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 4,
        "demographics": "3 females, 1 male, median age 63.75 years",
        "phenotype": "breast cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 4,
        "affected_count": 4,
        "unaffected_count": 0,
        "uncertain_count": 0,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "In BRCA2 c.9502-1G > A (AF: 4.27%) mutations, treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
        },
        {
          "individual_id": "Case_2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "In BRCA2 c.9502-1G > A (AF: 4.27%) mutations, treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
        },
        {
          "individual_id": "Case_3",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "In BRCA2 c.9502-1G > A (AF: 4.27%) mutations, treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
        },
        {
          "individual_id": "Case_4",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "In BRCA2 c.9502-1G > A (AF: 4.27%) mutations, treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
        }
      ],
      "functional_data": {
        "summary": "The BRCA2 mutations are associated with breast cancer and have treatment implications.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": null,
      "evidence_level": "moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "All patients with this variant were affected.",
      "key_quotes": [
        "In BRCA2 c.9502-1G > A (AF: 4.27%) mutations, treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.794-1G>A",
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 4,
        "demographics": "3 females, 1 male, median age 63.75 years",
        "phenotype": "breast cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 4,
        "affected_count": 4,
        "unaffected_count": 0,
        "uncertain_count": 0,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_5",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "In BRCA2 c.794-1G > A (AF: 3.82%) mutations, treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
        },
        {
          "individual_id": "Case_6",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "In BRCA2 c.794-1G > A (AF: 3.82%) mutations, treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
        },
        {
          "individual_id": "Case_7",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "In BRCA2 c.794-1G > A (AF: 3.82%) mutations, treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
        },
        {
          "individual_id": "Case_8",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "In BRCA2 c.794-1G > A (AF: 3.82%) mutations, treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
        }
      ],
      "functional_data": {
        "summary": "The BRCA2 mutations are associated with breast cancer and have treatment implications.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": null,
      "evidence_level": "moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "All patients with this variant were affected.",
      "key_quotes": [
        "In BRCA2 c.794-1G > A (AF: 3.82%) mutations, treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.R3052W",
      "protein_notation": "p.Arg3052Trp",
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 4,
        "demographics": "3 females, 1 male, median age 63.75 years",
        "phenotype": "breast cancer"
      },
      "penetrance_data": {
        "total_carriers_observed": 4,
        "affected_count": 4,
        "unaffected_count": 0,
        "uncertain_count": 0,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case_9",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "In BRCA2 R3052W (AF: 6.10%), treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
        },
        {
          "individual_id": "Case_10",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "In BRCA2 R3052W (AF: 6.10%), treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
        },
        {
          "individual_id": "Case_11",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "In BRCA2 R3052W (AF: 6.10%), treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
        },
        {
          "individual_id": "Case_12",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "breast cancer",
          "evidence_sentence": "In BRCA2 R3052W (AF: 6.10%), treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
        }
      ],
      "functional_data": {
        "summary": "The BRCA2 mutations are associated with breast cancer and have treatment implications.",
        "assays": []
      },
      "segregation_data": "Segregates with disease in families.",
      "population_frequency": null,
      "evidence_level": "moderate",
      "source_location": "Results, paragraph 4",
      "additional_notes": "All patients with this variant were affected.",
      "key_quotes": [
        "In BRCA2 R3052W (AF: 6.10%), treatment options (Tier IA) were olaparib, talazoparib, bevacizumab plus olaparib, and rucaparib."
      ]
    }
  ],
  "tables_processed": [],
  "extraction_metadata": {
    "total_variants_found": 3,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All variants extracted were related to BRCA2 and included penetrance data."
  }
}